Joseph J. Wanford

Joseph J. Wanford

Auto-generated profile, based on publicly available information

Joseph J. Wanford

Department of Genetics and Genome Biology, University of Leicester, Leicester, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
GEGiuseppe Ercoli
Giuseppe Ercoli
VFVitor E. Fernandes
Vitor E. Fernandes
WCWen Y. Chung
Wen Y. Chung
JWJoseph J. Wanford
Joseph J. Wanford
STSarah Thomson
Sarah Thomson
MOMarco Oggioni
Marco Oggioni

1 December 2017 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
NHNothaft Harald
Nothaft Harald
MPM. E. Perez-Muñoz
M. E. Perez-Muñoz
GGG. J. Gouveia
G. J. Gouveia
RDRebbeca Duar
Rebbeca Duar
JWJ. J. Wanford
J. J. Wanford
CSChristine Szymanski
Christine Szymanski
Source attribution studies report that the consumption of contaminated poultry is the primary source for acquiring human campylobacteriosis. Oral administration of an engineeredEscherichia colistrain expressing theCampylobacter jejuniN-glycan reduces bacterial colonization in specific-pathogen-free leghorn chickens, but only a fraction of birds respond to vaccination. Optimization of the vaccine for commercial broiler chickens has great potential to prevent the entry of the pathogen into the food chain. Here, we tested the same vaccination approach in broiler chickens and observed similar efficacies in pathogen load reduction, stimulation of the host IgY response, the lack ofC. jejuniresistance development, uniformity in microbial gut composition, and the bimodal response to treatment. Gut microbiota analysis of leghorn and broiler vaccine responders identified one member ofClostridialescluster XIVa,Anaerosporobacter mobilis, that was significantly more abundant in responder birds. In broiler chickens, coadministration of the live vaccine withA. mobilisorLactobacillus reuteri, a commonly used probiotic, resulted in increased vaccine efficacy, antibody responses, and weight gain. To investigate whether the responder-nonresponder effect was due to the selection of aC. jejuni“supercolonizer mutant” with altered phase-variable genes, we analyzed all poly(G)-containing loci of the input strain compared to nonresponder colony isolates and found no evidence of phase state selection. However, untargeted nuclear magnetic resonance (NMR)-based metabolomics identified a potential biomarker negatively correlated withC. jejunicolonization levels that is possibly linked to increased microbial diversity in this subgroup. The comprehensive methods used to examine the bimodality of the vaccine response provide several opportunities to improve theC. jejunivaccine and the efficacy of any vaccination strategy.IMPORTANCECampylobacter jejuniis a common cause of human diarrheal disease worldwide and is listed by the World Health Organization as a high-priority pathogen.C. jejuniinfection typically occurs through the ingestion of contaminated chicken meat, so many efforts are targeted at reducingC. jejunilevels at the source. We previously developed a vaccine that reducesC. jejunilevels in egg-laying chickens. In this study, we improved vaccine performance in meat birds by supplementing the vaccine with probiotics. In addition, we demonstrated thatC. jejunicolonization levels in chickens are negatively correlated with the abundance of clostridia, another group of common gut microbes. We describe new methods for vaccine optimization that will assist in improving theC. jejunivaccine and other vaccines under development.

11 June 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
LFL J Farrell
L J Farrell
RLR Lo
R Lo
JWJ J Wanford
J J Wanford
AJA Jenkins
A Jenkins
AMA Maxwell
A Maxwell
LPLaura Piddock
Laura Piddock
The current state of antibiotic discovery, research and development is insufficient to respond to the need for new treatments for drug-resistant bacterial infections. The process has changed over the last decade, with most new agents that are in Phases 1-3, or recently approved, having been discovered in small- and medium-sized enterprises or academia. These agents have then been licensed or sold to large companies for further development with the goal of taking them to market. However, early drug discovery and development, including the possibility of developing previously discontinued agents, would benefit from a database of antibacterial compounds for scrutiny by the developers. This article describes the first free, open-access searchable database of antibacterial compounds, including discontinued agents, drugs under pre-clinical development and those in clinical trials: AntibioticDB (AntibioticDB.com). Data were obtained from publicly available sources. This article summarizes the compounds and drugs in AntibioticDB, including their drug class, mode of action, development status and propensity to select drug-resistant bacteria. AntibioticDB includes compounds currently in pre-clinical development and 834 that have been discontinued and that reached varying stages of development. These may serve as starting points for future research and development.

1 June 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
NONeil Oldfield
Neil Oldfield
CCCaroline Cayrou
Caroline Cayrou
MAMahab A.K. AlJannat
Mahab A.K. AlJannat
AAAli A.A. Al-Rubaiawi
Ali A.A. Al-Rubaiawi
LGLuke R. Green
Luke R. Green
DTDavid P.J. Turner
David P.J. Turner
MenACWY conjugate vaccination was recently introduced in the United Kingdom for adolescents and young adults to reduce disease from infection by Neisseria meningitidis group W. We conducted a cross-sectional meningococcal carriage study in first-year UK university students. Despite 71% MenACWY vaccine coverage, carriage of group W increased substantially.

15 May 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JWJoseph J Wanford
Joseph J Wanford
LGLuke R. Green
Luke R. Green
JAJack Aidley
Jack Aidley
CBChristopher David Bayliss
Christopher David Bayliss
Pathogenic Neisseria are responsible for significantly higher levels of morbidity and mortality than their commensal relatives despite having similar genetic contents. Neisseria possess a disparate arsenal of surface determinants that facilitate host colonisation and evasion of the immune response during persistent carriage. Adaptation to rapid changes in these hostile host environments is enabled by phase variation (PV) involving high frequency, stochastic switches in expression of surface determinants. In this study, we analysed 89 complete and 79 partial genomes, from the NCBI and Neisseria PubMLST databases, representative of multiple pathogenic and commensal species of Neisseria using PhasomeIt, a new program that identifies putatively phase-variable genes and homology groups by the presence of simple sequence repeats (SSR). We detected a repertoire of 884 putative PV loci with maxima of 54 and 47 per genome in gonococcal and meningococcal isolates, respectively. Most commensal species encoded a lower number of PV genes (between 5 and 30) except N. lactamica wherein the potential for PV (36–82 loci) was higher, implying that PV is an adaptive mechanism for persistence in this species. We also characterised the repeat types and numbers in both pathogenic and commensal species. Conservation of SSR-mediated PV was frequently observed in outer membrane proteins or modifiers of outer membrane determinants. Intermittent and weak selection for evolution of SSR-mediated PV was suggested by poor conservation of tracts with novel PV genes often occurring in only one isolate. Finally, we describe core phasomes—the conserved repertoires of phase-variable genes—for each species that identify overlapping but distinctive adaptive strategies for the pathogenic and commensal members of the Neisseria genus.

17 March 2020 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
MCMegan De Ste Croix
Megan De Ste Croix
JHJonathan Holmes
Jonathan Holmes
JWJoseph J. Wanford
Joseph J. Wanford
EME. Richard Moxon
E. Richard Moxon
MOMarco R. Oggioni
Marco R. Oggioni
CBChristopher David Bayliss
Christopher David Bayliss
Bottlenecks reduce the size of the gene pool within populations of all life forms with implications for their subsequent survival. Here, we examine the effects of bottlenecks on bacterial commensal‐pathogens during transmission between, and dissemination within, hosts. By reducing genetic diversity, bottlenecks may alter individual or population‐wide adaptive potential. A diverse range of hypermutable mechanisms have evolved in infectious agents that allow for rapid generation of genetic diversity in specific genomic loci as opposed to the variability arising from increased genome‐wide mutation rates. These localised hypermutable mechanisms include multi‐gene phase variation (PV) of outer membrane components, multi‐allele PV of restriction systems and recombination‐driven antigenic variation. We review selected experimental and theoretical (mathematical) models pertaining to the hypothesis that localised hypermutation (LH) compensates for fitness losses caused by bottlenecks and discuss whether bottlenecks have driven the evolution of hypermutable loci.